BiondVax Pharmaceuticals (BVXV) Earns Media Sentiment Score of 0.08
News headlines about BiondVax Pharmaceuticals (NASDAQ:BVXV) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.7287896973439 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
BiondVax Pharmaceuticals (BVXV) opened at 8.45 on Wednesday. The firm has a 50-day moving average price of $8.89 and a 200-day moving average price of $6.89. The company’s market capitalization is $34.32 million. BiondVax Pharmaceuticals has a 52 week low of $3.04 and a 52 week high of $10.75.
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.